
The company says the separation will create a listed nutrition business and leave Abbott focused on devices, diagnostics and medicines.
Abbott Laboratories plans to separate its nutrition business into an independent, publicly traded company by the end of 2027, the company said Wednesday.
The new company would include brands such as Similac, PediaSure and Ensure. Abbott said the business generated about $8.5 billion in annual sales and had around 16,000 employees.
Abbott expects one-time costs before the separation, but has not disclosed their size. The company said the planned transaction will not affect its 2026 earnings forecast or its 2027 outlook, which it plans to issue in January.
As of 15:58 UTC on Wednesday, Abbott shares traded at $98.26, down 4.09% since the previous close.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.